Report Highlights
The global market for RNA analysis/transcriptomics should grow from $8.3 billion in 2021 to $13.4 billion by 2026, at compound annual growth rate (CAGR) of 9.9% for the period of 2021-2026.
Report Includes
- 41 tables
- An overview of the global RNA analysis/transcriptomics market
- Analyses of global market trends, with data from 2019, 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Detailed analysis of the current market trends and forecast, relevant R&D activities, new products launches and product enhancement in the industry and discussion of regulatory elements that are affecting the future marketplace
- Detailed description of RNA analysis types such as microarrays, polymerase chain reaction (PCR), sequencing technologies, and RNAI gene silencing, and coverage of their industry structure
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Company profiles of major players in the market including Agilent Technologies Inc., Bio-Rad Laboratories Inc., CD Genomics, Danaher, Roche, Illumina Inc., Merck KGAA, Qiagen, Thermo Fisher Scientific Inc.
Report Scope
This study offers a global view of the RNA analysis for various applications. This report analyzes and assesses different types of RNA analysis involved, namely microarrays, polymerase chain reaction (PCR), sequencing technologies, and RNAi gene silencing. It also provides information by application, categorized as clinical diagnosis, drug discovery and toxicogenomics.
BCC Research analyzed and made projections for each market and its type, new products and technological advances. Also included in the report are a discussion of the impact of COVID-19 on the market and profiles of leading companies in the RNA analysis market. The leading firms in the market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Bio-Rad Laboratories, CD Genomics, Promega Corp., Illumina Inc., Qiagen NV, Danaher Corp., F. Hoffmann-La Roche Ltd., Merck KGaA, Fluidigm Corp., and Eurofins Scientific.
By region, this report is broken down into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA).
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- Alzheimer's Disease Therapeutics and Diagnostics: Global Markets (PHM062E)
- Impact Modifiers: Global Markets (AVM252A)
- Adhesives and Adhesive-Applying Equipment: Technologies and Global Markets (CHM073E)
- Bioprocess Optimization and Digital Bio-manufacturing: Global Markets (BIO170B)
- Metal-organic Frameworks: Global Markets (AVM200B)
Related Reports
RNA Sequencing: Technologies and Global Markets
The global market for RNA sequencing is expected to grow from $4.3 billion in 2024 and is projected to reach $10.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.1% during the forecast period of 2024 to 2029.
RNAi Technologies and Global Markets
The global market for RNAi technology is estimated to increase from $2.1 billion in 2023 to reach $4.8 billion by 2029, at a compound annual growth rate (CAGR) of 14.8% from 2024 through 2029.
mRNA: Therapeutics and Global Markets
The global market for mRNA therapeutics is expected to decline from $33 billion in 2023 to $21 billion by the end of 2028, at a compound annual growth rate (CAGR) of -8.6% during the forecast period of 2023-2028.
RNAi Drug Delivery: Technologies and Global Markets
The global nucleic acid drug delivery market should reach $2.7 billion by 2028 from $1.1 billion in 2023 at a compound annual growth rate (CAGR) of 20.5% for the forecast period of 2023 to 2028.
Recent Reports
Bioprocess Optimization and Digital Bio-manufacturing: Global Markets
The global market for bioprocess optimization and digital biomanufacturing is expected to grow from $24.3 billion in 2024 and is projected to reach $39.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2024 to 2029.
Global DNA Sequencing: Research, Applied and Clinical Markets
The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.
Artificial Intelligence (AI) in Cancer
The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More